Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
VERTAVIS vs ISMO
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Vertavis is an inhibitor of acetylcholinesterase, increasing acetylcholine levels at cholinergic synapses.
Isosorbide mononitrate is a nitrate that dilates coronary arteries and peripheral veins. It acts by releasing nitric oxide, which activates guanylate cyclase, increasing c GMP levels, leading to smooth muscle relaxation and vasodilation.
Treatment of mild to moderate Alzheimer's disease,Off-label: treatment of other dementias, myasthenia gravis
Prevention of angina pectoris due to coronary artery disease,Off-label: Treatment of acute angina (immediate-release forms)
5 mg orally three times daily. May be increased to 10 mg three times daily if tolerated.
20 mg orally twice daily, 7 hours apart (e.g., 8 AM and 3 PM) to minimize nitrate tolerance.
Terminal elimination half-life is 39–58 hours (mean 49 hours), supporting once-daily dosing. Steady state is achieved after 7–10 days.
Terminal elimination half-life is approximately 5-6 hours. In elderly patients or those with hepatic impairment, half-life may be prolonged (up to 8-10 hours), warranting dose adjustment.
Primarily hydrolyzed by plasma esterases; minor hepatic metabolism via CYP450 enzymes.
Primarily metabolized in the liver by denitration; minor metabolism via glucuronidation. Metabolites are inactive.
Approximately 70% of the dose is excreted renally as unchanged drug and 30% via biliary/fecal routes as metabolites.
Primarily renal; 80-90% of the dose is excreted as inactive metabolites (isosorbide mononitrate and isosorbide dinitrate) in urine. Less than 1% is excreted unchanged. Fecal excretion is minimal.
Approximately 99% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Approximately 30% bound to plasma proteins, primarily albumin.
Volume of distribution is 0.4–0.6 L/kg (approx 30–50 L in adults), indicating distribution primarily into extracellular fluid.
Vd is 0.6-0.9 L/kg, indicating distribution into total body water. Higher Vd may be observed in patients with heart failure.
Oral bioavailability is approximately 50% (range 30–70%) with food reducing rate but not extent of absorption.
Oral: 90-100% (sustained-release formulations). Sublingual: high but variable; generally effective due to extensive absorption.
No dose adjustment required for mild to moderate renal impairment. For severe renal impairment (e GFR <30 m L/min/1.73 m²), use is not recommended.
No dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, consider reducing dose to 10 mg twice daily due to potential accumulation of active metabolite.
Not recommended for use in patients with moderate to severe hepatic impairment (Child-Pugh class B or C). No data available.
No dose adjustment in Child-Pugh A or B. For Child-Pugh C, reduce dose to 10 mg twice daily and monitor for hypotension.
Safety and efficacy not established; no recommended dose.
Safety and efficacy not established; no standard dosing recommendations.
No specific dose adjustment; use with caution due to potential increased sensitivity and comorbidities.
Start at 10 mg twice daily with gradual titration based on tolerance and renal function. Monitor for hypotension and dizziness.
No FDA black box warning.
Do not use with phosphodiesterase-5 (PDE-5) inhibitors (e.g., sildenafil, tadalafil) due to risk of severe hypotension.
Cardiovascular effects (bradycardia, syncope),Gastrointestinal effects (nausea, vomiting, diarrhea),Seizures,Weight loss
Hypotension and reflex tachycardia may occur,Caution in patients with volume depletion or hypotension,May cause headaches; tolerance may develop with prolonged use,Abrupt withdrawal may increase angina frequency
Hypersensitivity to Vertavis or any component,History of severe cholinergic adverse effects
Concurrent use of PDE-5 inhibitors,Severe anemia,Closed-angle glaucoma,Hypersensitivity to isosorbide mononitrate or nitrates,Acute myocardial infarction with low filling pressures
Avoid grapefruit and grapefruit juice as they may increase ergotamine levels and risk of toxicity. Limit caffeine intake as it can exacerbate headache and interact with ergotamine. Avoid tyramine-rich foods (aged cheese, cured meats, fermented products) if migraines are triggered by tyramine.
Alcohol may enhance hypotension risk. Avoid high-fat meals if extended-release formulation, as they may affect absorption. No other significant food interactions.
Contraindicated in pregnancy. FDA Pregnancy Category X. In animals, ribociclib (active ingredient) caused embryotoxicity, fetotoxicity, and teratogenicity at maternal exposures below human clinical exposure at 400 mg/day. First trimester: high risk of major congenital malformations; second and third trimesters: risk of fetal growth restriction and fetal death.
ISMO (isosorbide mononitrate) is categorized as FDA Pregnancy Category C. In animal studies, reduced fetal survival and growth retardation were observed at high doses. No adequate human studies exist. Use only if potential benefit justifies risk. First trimester: Theoretical risk of hemodynamic effects; avoid unless necessary. Second/third trimester: May cause fetal hypoxia due to maternal hypotension; monitor fetal heart rate. Peripartum: May exacerbate uterine relaxation and postpartum hemorrhage if used near delivery.
Contraindicated during breastfeeding. No data on presence in human milk; however, animal studies show drug and metabolites are excreted in milk. M/P ratio not known. Due to potential for serious adverse reactions in breastfed infants, advise women not to breastfeed during treatment and for at least 3 weeks after last dose.
Excretion into human milk is unknown. Due to risk of infant methemoglobinemia and hypotension, caution is advised. M/P ratio: Not available. American Academy of Pediatrics considers nitrate derivatives compatible with breastfeeding, but monitor infant for cyanosis and lethargy.
No dose adjustments recommended during pregnancy as the drug is contraindicated. If unintentionally exposed, discontinue immediately. Physiologic changes in pregnancy may alter drug pharmacokinetics (e.g., increased volume of distribution, increased hepatic clearance), but no specific dose adjustment has been studied in pregnant women.
No specific dose adjustments for ISMO in pregnancy are established due to lack of pharmacokinetic studies. However, pregnancy-induced hemodynamic changes (increased plasma volume, cardiac output) may reduce efficacy; consider dose titration based on clinical response. Avoid doses >60 mg/day to minimize hypotensive risk. Use immediate-release formulations for flexible dosing if needed.
Vertavis (a combination of phenobarbital, ergotamine, and belladonna alkaloids) is used for migraine and tension-type headaches. Monitor for signs of ergotism (numbness, cold extremities, muscle pain) due to ergotamine; avoid prolonged use. Phenobarbital is a controlled substance (C-IV) with abuse potential; monitor for sedation and dependence. Belladonna alkaloids cause anticholinergic effects (dry mouth, blurred vision, urinary retention). Taper dose to avoid withdrawal; avoid in patients with peripheral vascular disease, coronary artery disease, or glaucoma.
ISMO (isosorbide mononitrate) is a nitrate used for angina prophylaxis, not for acute attacks. Tolerance develops with sustained use; maintain a 10-12 hour nitrate-free interval to prevent tolerance. Do not use with phosphodiesterase-5 inhibitors (e.g., sildenafil) due to risk of profound hypotension. Contraindicated in severe anemia, increased intracranial pressure, or hypertrophic obstructive cardiomyopathy. Discontinue if blurred vision or dry mouth occurs.
Take Vertavis at the first sign of headache; do not exceed recommended dose.,Do not use more than 10 days per month to avoid medication-overuse headache and ergotamine toxicity.,Report symptoms of ergotism such as cold fingers or toes, numbness, tingling, or muscle pain immediately.,This medication may cause drowsiness or dizziness; avoid driving or operating machinery until you know how you react.,Avoid alcohol; it can increase sedation and ergotamine side effects.,Do not suddenly stop taking this medication; withdrawal may cause rebound headaches or seizures.
Take as prescribed to prevent angina; do not use for acute attacks.,May cause headache, dizziness, or hypotension; rise slowly from sitting.,Avoid taking erectile dysfunction drugs (e.g., sildenafil, tadalafil) as severe blood pressure drop can occur.,Do not stop abruptly to avoid rebound angina.,Store in original container away from light and moisture.
No interactions on record
"Bosentan, a dual endothelin receptor antagonist and an inducer of CYP3A4 and CYP2C9, reduces systemic exposure to vismodegib, a Hedgehog pathway inhibitor primarily metabolized by CYP3A4. This interaction leads to decreased serum concentrations of vismodegib, potentially diminishing its antitumor efficacy in patients with advanced basal cell carcinoma. Concomitant use may require vismodegib dose adjustment or alternative therapies to avoid therapeutic failure."
"Vismodegib inhibits CYP3A4, which is the primary enzyme responsible for metabolizing nilotinib. Concomitant administration may lead to increased nilotinib plasma concentrations, elevating the risk of QT interval prolongation, torsades de pointes, hepatotoxicity, and myelosuppression. Clinical vigilance is warranted due to the narrow therapeutic index of nilotinib."
"Vismodegib, a hedgehog pathway inhibitor, is a moderate inhibitor of CYP2C9, the primary enzyme responsible for metabolizing tolbutamide. Concomitant use can significantly decrease tolbutamide clearance, leading to elevated plasma concentrations and prolonged hypoglycemic effects. This increases the risk of severe hypoglycemia, especially in diabetic patients, and may require dose adjustment of tolbutamide."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about VERTAVIS vs ISMO, answered by our medical review team.
VERTAVIS is a Prostacyclin Vasodilator that works by Vertavis is an inhibitor of acetylcholinesterase, increasing acetylcholine levels at cholinergic synapses.. ISMO is a Nitrate Vasodilator that works by Isosorbide mononitrate is a nitrate that dilates coronary arteries and peripheral veins. It acts by releasing nitric oxide, which activates guanylate cyclase, increasing c GMP levels, leading to smooth muscle relaxation and vasodilation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between VERTAVIS and ISMO depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of VERTAVIS is: 5 mg orally three times daily. May be increased to 10 mg three times daily if tolerated.. The standard adult dose of ISMO is: 20 mg orally twice daily, 7 hours apart (e.g., 8 AM and 3 PM) to minimize nitrate tolerance.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between VERTAVIS and ISMO in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. VERTAVIS is classified as Category C. Contraindicated in pregnancy. FDA Pregnancy Category X. In animals, ribociclib (active ingredient) caused embryotoxicity, fetotoxicity, and teratogenicity at maternal exposures bel. ISMO is classified as Category C. ISMO (isosorbide mononitrate) is categorized as FDA Pregnancy Category C. In animal studies, reduced fetal survival and growth retardation were observed at high doses. No adequate . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.